A rationale for reduced-frequency dosing of anidulafungin for antifungal prophylaxis in immunocompromised patients | Zendy

Roger J. M. Brüggemann | Zendy; Walter J. F. M. van der Velden | Zendy; Catherijne A. J. Knibbe | Zendy; Angela Colbers | Zendy; S. Hol | Zendy; David M. Burger | Zendy; J. Peter Donnelly | Zendy; Nicole M. A. Blijlevens | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

A rationale for reduced-frequency dosing of anidulafungin for antifungal prophylaxis in immunocompromised patients

Author(s) -

Roger J. M. Brüggemann,

Walter J. F. M. van der Velden,

Catherijne A. J. Knibbe,

Angela Colbers,

S. Hol,

David M. Burger,

J. Peter Donnelly,

Nicole M. A. Blijlevens

Publication year - 2014

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dku477

Subject(s) - anidulafungin , dosing , medicine , pharmacokinetics , regimen , volume of distribution , population , pharmacology , intensive care medicine , antifungal , amphotericin b , micafungin , environmental health , dermatology

Reduced-frequency dosing strategies of anidulafungin may offer a more convenient way of providing adequate antifungal prophylaxis to patients at high risk of invasive fungal diseases. We aimed to provide the pharmacological rationale for the applicability of reduced-frequency dosing regimens.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research